Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Bristol-Myers Squibb Co (BMY) vs KLA Corp. (KLAC) Price & Performance

Bristol-Myers Squibb CoTrade

Price performance (Past 24H)

Key statistics

Bristol-Myers Squibb Co vs KLA Corp. — how do they compare? Bristol-Myers Squibb Co trades at $63.69 (market cap $129.94B), while KLA Corp. trades at $207.66 (market cap $261.92B). The key difference: KLA Corp. is far larger — about 2× Bristol-Myers Squibb Co's market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.96%). Which is the better fit depends on your goals.

BMYKLAC
Market Cap
$129.94B$261.92B
Sector
HealthTechnology
52-Week High
$65.89$301.71
52-Week Low
$42.60$84.39
Enterprise Value
$163.92B$263.17B
Dividend Yield
3.96%0.46%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Bristol-Myers Squibb Co

Bristol Myers Squibb (BMY) trades at $64.84, up 0.19% today, with a bullish technical signal from moving averages and strong fundamental health evidenced by a 14.01 P/E ratio and 18.87% net income margin. Recent earnings beats and a $2.3 billion manufacturing investment in Houston highlight operational strength, while analyst consensus is mixed with a $68.56 price target.

The outlook is positive due to earnings momentum and strategic investments, but risks include patent expirations and high debt levels. Wall Street sentiment is cautiously optimistic, with institutional buying supporting the stock's potential for moderate upside from current levels.

KLA Corp.

KLA Corporation (KLAC) trades at $192.74, down 2.71% on the day, amid a broader semiconductor sector pullback. The stock shows strong fundamentals with revenue growth to $12.16B in 2025 and net income of $4.06B, though valuation ratios remain elevated with a P/E of 54.77. Recent corporate actions include a 1:10 stock split and dividend declarations, while technical indicators signal near-term bearish pressure with key support at $189.

KLAC presents a compelling long-term investment case driven by AI-driven semiconductor equipment demand and consistent earnings beats, but faces risks from high valuation and sector volatility. Analyst consensus remains bullish with a $246.93 price target implying 28% upside, though investors should monitor execution against growth expectations and competitive dynamics in the semiconductor equipment space.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Bristol-Myers Squibb Co

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.

Read more on BMY

About KLA Corp.

KLA designs and manufactures yield-management and process-monitoring diagnostic and control systems for the semiconductor manufacturing industry. The systems are used to analyze the manufacturing process at various steps in a semiconductor's development. The firm's laser-scanning products are used for wafer qualification, process monitoring, and equipment monitoring. KLA also provides inspection tools and systems for optical metrology and e-beam metrology.

Read more on KLAC